Results are the first from a cardiovascular safety trial in the GLP-1 agonist class. A commentator at the 75th Scientific Sessions of the American Diabetes Association asked whether the FDA-mandated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results